Literature DB >> 18930510

[Association of Parry-Romberg syndrome and paroxymal kinesigenic dyskinesia].

H Mrabet Khiari1, S Masmoudi, A Mrabet.   

Abstract

INTRODUCTION: Parry-Romberg syndrome is a rare entity of unknown etiology, characterized by hemifacial or hemibody atrophy affecting subcutaneous tissues. Its main clinical manifestations are neurological, ocular and dermatological. Paroxysmal kinesigenic dyskinesia (PKD) is characterized by brief episodes of choreic/dystonic movements triggered by sudden movements and improved by antiepileptic drugs particularly carbamazepine. It can be sporadic or familial with an autosomal dominant inheritance. Little is known about the pathophysiology of PKD, although a channelopathy is thought likely. The association of these two diseases is rare. CASE REPORT: Over three years, a 42-year-old patient progressively developed left hemiatrophy. Since age 14, he presented paroxysmal dystonic disorders of the limbs triggered by sudden movements and controlled by carbamazepine. The diagnosis of PKD associated with Parry-Romberg syndrome was established. Investigations revealed immunologic and diffuse electrophysiological abnormalities (EEG and EMG).
CONCLUSION: PKD associated with Parry-Romberg syndrome is very rare but does not appear to be fortuitous. It suggests a common mechanism via an underlying channelopathy or dysimmune disorder.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18930510     DOI: 10.1016/j.neurol.2008.08.003

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  2 in total

1.  Clinical analysis of nine cases of paroxysmal exercise-induced dystonia.

Authors:  Guoping Peng; Kang Wang; Yuan Yuan; Xuning Zheng; Benyan Luo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-12-28

2.  Neurological Manifestations in Parry-Romberg Syndrome: 2 Case Reports.

Authors:  Justine Vix; Stéphane Mathis; Mathieu Lacoste; Rémy Guillevin; Jean-Philippe Neau
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.